Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Authors
Keywords
-
Journal
Diabetology & Metabolic Syndrome
Volume 15, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-30
DOI
10.1186/s13098-023-01198-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
- (2023) Leili Gao et al. NATURE MEDICINE
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- (2023) W Timothy Garvey et al. LANCET
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of tirzepatide 5, 10, and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison
- (2022) Karan Vadher et al. DIABETES OBESITY & METABOLISM
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
- (2022) Thomas Karagiannis et al. DIABETOLOGIA
- SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
- (2022) Jun Sung Moon et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
- (2022) Tim Heise et al. Lancet Diabetes & Endocrinology
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
- (2022) Amalia Gastaldelli et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
- (2022) Nobuya Inagaki et al. Lancet Diabetes & Endocrinology
- Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
- (2022) Michael A. Nauck et al. Cardiovascular Diabetology
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
- (2021) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
- (2021) Kenichi Furihata et al. DIABETES OBESITY & METABOLISM
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
- (2021) Ildiko Lingvay et al. LANCET
- Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
- (2021) Akshaya Srikanth Bhagavathula et al. Pharmaceuticals
- Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
- (2020) Juan Pablo Frias et al. DIABETES OBESITY & METABOLISM
- GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists
- (2020) Jens Juul Holst et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- (2020) Francis S. Willard et al. JCI Insight
- The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
- (2020) Jonathan M. Wilson et al. DIABETES OBESITY & METABOLISM
- Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial
- (2019) Michael E J Lean et al. Lancet Diabetes & Endocrinology
- „Diabesity“ – Adipositas und Typ-2-Diabetes (Update 2019)
- (2019) Hermann Toplak et al. WIENER KLINISCHE WOCHENSCHRIFT
- Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
- (2019) Marie Bastin et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
- (2019) Lærke S. Gasbjerg et al. PEPTIDES
- Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management
- (2018) Yang T. Du et al. DIABETES CARE
- Glucose-dependent insulinotropic polypeptide increases blood flow in adipose tissue of humans by recruiting capillaries
- (2018) Meena Asmar et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
- (2018) Michael EJ Lean et al. LANCET
- Glucagon-like peptide 1 in health and disease
- (2018) Andreas Andersen et al. Nature Reviews Endocrinology
- Metabolic and Bariatric Surgery: An Effective Treatment Option for Obesity and Cardiovascular Disease
- (2018) Wayne J. English et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Peptide-based multi-agonists: a new paradigm in metabolic pharmacology
- (2018) Sara J. Brandt et al. JOURNAL OF INTERNAL MEDICINE
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Reappraisal of GIP Pharmacology for Metabolic Diseases
- (2016) Brian Finan et al. TRENDS IN MOLECULAR MEDICINE
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
- (2013) B. Finan et al. Science Translational Medicine
- GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
- (2012) Su-Jin Kim et al. PLoS One
- Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
- (2011) M. Christensen et al. DIABETES
- Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
- (2010) M. Asmar et al. DIABETES
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
- (2009) A. Pocai et al. DIABETES
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- (2009) Jonathan W Day et al. Nature Chemical Biology
- Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
- (2008) P. V. Højberg et al. DIABETOLOGIA
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
- (2008) W. Kim et al. PHARMACOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation